Paul Webb, Ph.D.
Associate Professor of Biochemisty in Medicine
Postdoctoral Research Fellowship, Immunology Department, University of California, San Francisco, San Francisco, CA
After completion of his fellowship in the Metabolic Research Unit at the University of California at San Francisco (UCSF) in 1994, Dr. Webb joined the permanent research staff there in the laboratory of Dr. John Baxter. He rose through the ranks and, in 1999, became an Assistant Research Biochemist Level IV. In 2001, Dr. Webb joined the Diabetes Center at UCSF where he was quickly promoted to an Associate Researcher Level IV. He spent a year as a visiting professor in Biochemistry at the University of San Francisco in 2005 where he taught several courses in biochemistry. Since 2001, Dr. Webb has served as laboratory co-director with Dr. Baxter. He has co-written over 60 manuscripts that have been published in peer-reviewed publications, and is currently Co-PI on three NIH grants. Dr. Webb assumed his current positions at The Methodist Hospital Research Institute in 2007.
Dr. Webb's main research interests are investigations into the principles of nuclear hormone receptor structure and function, as well as studies of the actions of pharmaceutical agents to selectively modulate actions of these proteins. Research approaches include X-ray structural analysis, targeted mutagenesis to understand receptor structure, detailed analysis of gene expression and genome wide sequence interactions and collaborative studies to determine the metabolic effects of drugs in preclinical models.
Diabetes, nuclear hormone receptor, ligand design
Webb P. Another story of mice and men: the types of RTH. Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9129-30.
Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009 Apr;8(4):308-20. Review.
Shah V, Nguyen P, Nguyen NH, Togashi M, Scanlan TS, Baxter JD, Webb P. Complex actions of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines. Mol Cell Endocrinol. 2008 Dec 16;296(1-2):69-77
Jouravel N, Sablin E, Togashi M, Baxter JD, Webb P, Fletterick RJ. Molecular basis for dimer formation of TRbeta variant D355R. Proteins. 2009 Apr;75(1):111-7.
Jeyakumar M, Webb P, Baxter JD, Scanlan TS, Katzenellenbogen JA. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry. 2008 Jul 15;47(28):7465-76.
Estebanez-Perpina E, Arnold LA, Jouravel N, Togashi M, Blethrow J, Mar E, Nguyen P, Phillips KJ, Baxter JD, Webb P, Guy RK, Fletterick RJ. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol. 2007;21(12):2919-2928.